Novelfarma, headquartered in İstanbul, is an innovative and growth-oriented pharmaceutical company. Novelfarma is focused on developing, producing and delivering innovative medicines and medical devices to patients all over the world.
Novelfarma has an innovative product portfolio offering treatment solutions in the fields of rare and genetic diseases, medical aesthetics, dermatology, obesity, pediatric diseases, and digestive system diseases.
Novelfarma has a R&D approach aimed to development of the innovative product, more than 50 product development programs and close to 10 clinical study portfolio. Our goal is to have one of the largest new product portfolios in the pharmaceutical sector as an originator company.
Innovation and the capabilities of our employees form the basis of our successes. We maintain sustainability by producing new technologies, making an investment in R&D projects and supporting our employees’ progress.
Novelfarma supports innovation as well as investment in R&D studies. We produce more excessive innovation collaborating with prominent universities, public research institutions, and partner companies.
Novelfarma, continues works for licensing the products in its portfolio in European Union countries, America, African countries and Asian countries.
Novelfarma is conscious of its responsibilities and has adopted a sustainable business approach with all stakeholders in a human-oriented approach.
The logo of the Novelfarma is a combination of tulip figure which is the one of the symbols of our country all over the world and mortar figure which is the symbol of medicine and pharmacy.